Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Coherus Biosicences
Can Coherus invalidate Amgen's Enbrel® patents? Part 2

In an earlier post, we discussed the pending IPRs filed by Coherus Biosciences against Amgen’s two patents covering its Enbrel® protein (entanercept).  Whereas our earlier post summarized Coherus’s argument for why the fusion protein claimed in Amgen’s ‘182 and ‘522 patents should be found obvious by the PTAB, this post will summarize Amgen’s preliminary response. 

Read More
Markman AdvisorsEnbrel, entanercept, Coherus Biosicences, Amgen, protein, antibody, inter partes review, IPR, PTAB, kyle bass
Sandoz’s aBLA for HUMIRA® has been accepted by FDA -- what happens next?

Sandoz, the generic arm of Novartis, has announced that its abbreviated Biologic License Application (aBLA) for a Humira® biosimilar has been accepted by FDA.  Now that Sandoz’s aBLA has been accepted for review by FDA, what happens next on the patent front? 

Read More
Markman AdvisorsSandoz, Novartis, AbbVie, Humira, FDA, aBLA, BPCIA, Coherus, Coherus Biosicences, Boehringer-Ingelheim, patent dance, Enbrel, Neupogen, IPR, inter partes review, patent, biosimilar